A Metabolic Blueprint for Synergistic Cancer Therapy
In the fight against cancer, single-agent treatments often hit a wall as tumors adapt and develop resistance. This is especially true for aggressive cancers like non-small-cell lung cancer (NSCLC) with KRAS and LKB1 mutations, a hard-to-treat subtype. These challenges...
Metabolomics for Mechanism of Action: Understanding Drivers of Synergistic Inhibitor Treatment in Cancer
Metabolomics for Mechanism of Action in Synergistic Cancer Treatments Next-Generation Metabolomics can provide robust, biologically meaningful data for drug combination analysis. Learn more about treatment-induced metabolic reprogramming and targeted combination...
PRMT5 Metabolomics Panel for Patient Stratification
PRMT5 Metabolomics Panel for Patient Stratification This poster presents a targeted, multiplexed LC-MS/MS metabolomics assay developed to support patient stratification and pharmacodynamic monitoring for MTA-cooperative PRMT5 inhibitors in oncology research....